Open Access 01-12-2021 | Portal Vein Thrombosis | Letter to the Editors
Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis
Published in: Journal of Neurology | Issue 12/2021
Login to get access